INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 231 filers reported holding INOVIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,361 | -94.5% | 11,211 | -93.7% | 0.00% | – |
| Q2 2023 | $79,564 | -89.2% | 178,194 | -80.1% | 0.00% | -100.0% |
| Q1 2023 | $733,826 | -6.5% | 894,910 | +77.8% | 0.00% | 0.0% |
| Q4 2022 | $785,178 | -99.9% | 503,319 | -17.5% | 0.00% | -50.0% |
| Q3 2022 | $1,051,915,000 | +998.4% | 609,806 | +1001.6% | 0.00% | – |
| Q2 2022 | $95,769,000 | +18.7% | 55,358 | +146.3% | 0.00% | – |
| Q1 2022 | $80,692,000 | -79.6% | 22,477 | -71.7% | 0.00% | -100.0% |
| Q4 2021 | $396,251,000 | +5.4% | 79,409 | +51.2% | 0.00% | 0.0% |
| Q3 2021 | $376,043,000 | +63.0% | 52,520 | +111.0% | 0.00% | – |
| Q2 2021 | $230,702,000 | +8.2% | 24,887 | +8.3% | 0.00% | – |
| Q1 2021 | $213,273,000 | -58.2% | 22,982 | -60.2% | 0.00% | -100.0% |
| Q4 2020 | $510,663,000 | -82.5% | 57,702 | -77.1% | 0.00% | -75.0% |
| Q3 2020 | $2,924,082,000 | +523.7% | 252,076 | +1349.0% | 0.00% | +300.0% |
| Q2 2020 | $468,849,000 | +118.4% | 17,397 | -39.7% | 0.00% | – |
| Q1 2020 | $214,637,000 | +505.2% | 28,849 | +168.4% | 0.00% | – |
| Q4 2019 | $35,468,000 | +22.8% | 10,748 | -23.7% | 0.00% | – |
| Q3 2019 | $28,893,000 | +2.1% | 14,094 | +46.4% | 0.00% | – |
| Q2 2019 | $28,295,000 | -58.3% | 9,624 | -47.2% | 0.00% | – |
| Q1 2019 | $67,931,000 | +54683.1% | 18,212 | +58648.4% | 0.00% | – |
| Q4 2018 | $124,000 | -99.3% | 31 | -99.0% | 0.00% | – |
| Q3 2018 | $17,014,000 | +41.8% | 3,060 | 0.0% | 0.00% | – |
| Q2 2018 | $11,995,000 | -85.8% | 3,060 | -82.9% | 0.00% | – |
| Q1 2018 | $84,215,000 | +16.3% | 17,880 | +2.0% | 0.00% | – |
| Q4 2017 | $72,387,000 | +63.4% | 17,527 | +150.8% | 0.00% | – |
| Q3 2017 | $44,310,000 | -26.5% | 6,989 | -12.4% | 0.00% | – |
| Q2 2017 | $60,296,000 | +1901.9% | 7,981 | +1654.1% | 0.00% | – |
| Q1 2017 | $3,012,000 | -63.2% | 455 | -61.4% | 0.00% | – |
| Q4 2016 | $8,175,000 | -80.8% | 1,178 | -74.3% | 0.00% | – |
| Q3 2016 | $42,667,000 | +79.4% | 4,578 | +77.9% | 0.00% | – |
| Q2 2016 | $23,784,000 | -77.5% | 2,574 | -83.7% | 0.00% | – |
| Q4 2015 | $105,866,000 | +23.4% | 15,754 | +6.1% | 0.00% | – |
| Q3 2015 | $85,816,000 | +76.0% | 14,847 | +148.5% | 0.00% | – |
| Q2 2015 | $48,748,000 | +318.0% | 5,974 | +318.1% | 0.00% | – |
| Q1 2015 | $11,661,000 | -66.8% | 1,429 | -60.0% | 0.00% | – |
| Q3 2014 | $35,155,000 | – | 3,569 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |